The European Commission is complementing the successful EU Vaccines Strategy with a strategy on COVID-19 therapeutics to support the development and availability of medicines, including for the treatment of ‘long COVID’. This is a part of the European Health Union.
The European Commission identified 5 promising candidate therapeutics in June 2021, all of which are under rolling review or have applied for a new indication for an existing medicine to the European Medicines Agency.
An application for the extension of a marketing authorisation for COVID-19 indication is under assessment:
Newly developed monoclonal antibodies under rolling review (a regulatory tool to speed up the assessment of a promising medicine during a public health emergency):
- combination of bamlanivimab and etesevimab
- combination of casirivimab and imdevimab
As a next step, we will draw up a portfolio of 10 potential COVID-19 therapeutics by October. The European Commission is also organising matchmaking events for industrial actors involved in therapeutics. The new authorisations, rolling reviews and joint procurement contracts will be up and running before the end of the year.
For more information click here.